Next-Gen CAR T & Novel SMA Drug Among New Entrants On EMA’s PRIME
Rare Pediatric Disease Drug & Multiple Myeloma Therapy Also Make The Grade
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
You may also be interested in...
While the drug may be well-positioned for registrational development, some important caveats remain after mixed data in Phase II study cohorts.
The biotech has run low on funds after a difficult pandemic year, and is banking on its next-generation CAR-T therapy.
Vertex and CRISPR can now get access to the advantages afforded by the European Medicines Agency’s priority medicines scheme for both of the indications they are targeting with their investigational gene therapy, CTX001.